<em>Lactobacillus plantarum</em> LP45 inhibits the RANKL/OPG signaling pathway and prevents glucocorticoid-induced osteoporosis

Xiaofeng  Jiang; Xiaojun  Qi; Chao Xie

doi:10.29219/fnr.v67.9064

Xiaofeng Jiang Department of Joint Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
Xiaojun Qi Department of Joint Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
Chao Xie Department of Spine Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China

DOI: https://doi.org/10.29219/fnr.v67.9064

Keywords: bone, gut microbiota, inflammation, probiotics, Osteoporosis

Abstract

Objective: To examine the potential effect of the probiotic strain Lactobacillus plantarum LP45 on osteoporosis and to explore the involved molecular mechanisms.

Methods: A rat model of glucocorticoid-induced osteoporosis (GIO) was established, which was also orally administered with increasing doses of LP45 for 8 weeks. After the termination of the 8-week treatment, the tibia and femur bones of rats were analyzed for bone histomorphometry, bone mineral content (BMC), and bone mineral density (BMD). Femoral biomechanics were assessed. In addition, levels of osteocalcin, tartrate-resistant acid phosphatase 5 (TRAP5), osteoprotegerin (OPG), and receptor activator of nuclear factor kappa-B ligand (RANKL) in the serum and bone marrow were also measured using ELISA, Western blot, and real time-polymerase chain reaction.

Results: GIO caused obvious defects in tibia and femur bone structures, in terms of tissue/bone volume, trabecular separation, trabecular thickness, and trabecular number, which could be rescued by LP45 dose dependently. The GIO-induced reductions in BMC, BMD, osteoblast surfaces per bone surface (BS), as well as elevated osteoclast surface per BS were largely restored by LP45 administration dose-dependently. LP45 also increased femoral biomechanics of GIO rats. Importantly, LP45 dose-dependently restored the changes of osteocalcin, TRAP5, OPG, and RANKL in the serum as well as bone marrow of GIO rats.

Conclusion: Oral LP45 administration could significantly prevent bone defects in GIO rats, suggesting its potential as a dietary supplement with beneficial effects against osteoporosis, which might involve the RANKL/OPG signaling pathway.

Downloads

Download data is not yet available.

References

1.
den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2011; 13(3): 233–40. doi: 10.1007/s11926-011-0173-y

2.
Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377(9773): 1276–87. doi: 10.1016/S0140-6736(10)62349-5

3.
Martinez Perez JA, Palacios S, Garcia FC, Perez M. Assessing osteoporosis risk factors in Spanish menopausal women. Gynecol Endocrinol 2011; 27(10): 807–13. doi: 10.3109/09513590.2010.540599

4.
Schurer C, Wallaschofski H, Nauck M, Volzke H, Schober HC, Hannemann A. Fracture risk and risk factors for osteoporosis. Dtsch Arztebl Int 2015; 112(21–22): 365–71. doi: 10.3238/arztebl.2015.0365

5.
Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367(9527): 2010–18. doi: 10.1016/S0140-6736(06)68891-0

6.
Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 2013; 1(1): 59–70. doi: 10.1016/S2213-8587(13)70045-7

7.
Araya M, Morelli L, Reid G, Sanders M, Stanton C, Pineiro M, et al. Guidelines for the evaluation of probiotics in food. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London; 2002, pp. 1–11.

8.
Morelli L, Capurso L. FAO/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol 2012; 46(Suppl): S1–2. doi: 10.1097/MCG.0b013e318269fdd5

9.
Ohlsson C, Engdahl C, Fak F, Andersson A, Windahl SH, Farman HH, et al. Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS One 2014; 9(3): e92368. doi: 10.1371/journal.pone.0092368

10.
Zhang J, Motyl KJ, Irwin R, MacDougald OA, Britton RA, McCabe LR. Loss of bone and Wnt10b expression in male type 1 diabetic mice is blocked by the probiotic lactobacillus reuteri. Endocrinology 2015; 156(9): 3169–82. doi: 10.1210/EN.2015-1308

11.
Parvaneh K, Ebrahimi M, Sabran MR, Karimi G, Hwei AN, Abdul-Majeed S, et al. Probiotics (Bifidobacterium longum) increase bone mass density and upregulate sparc and Bmp-2 genes in rats with bone loss resulting from ovariectomy. Biomed Res Int 2015; 2015: 897639. doi: 10.1155/2015/897639

12.
Collins FL, Irwin R, Bierhalter H, Schepper J, Britton RA, Parameswaran N, et al. Lactobacillus reuteri 6475 increases bone density in intact females only under an inflammatory setting. PLoS One 2016; 11(4): e0153180. doi: 10.1371/journal.pone.0153180

13.
Yang LC, Lin SW, Li IC, Chen YP, Tzu SY, Chou W, et al. Lactobacillus plantarum GKM3 and Lactobacillus paracasei GKS6 supplementation ameliorates bone loss in ovariectomized mice by promoting osteoblast differentiation and inhibiting osteoclast formation. Nutrients 2020; 12(7): 1914. doi: 10.3390/nu12071914

14.
Lee CC, Liao YC, Lee MC, Lin KJ, Hsu HY, Chiou SY, et al. Lactobacillus plantarum TWK10 attenuates aging-associated muscle weakness, bone loss, and cognitive impairment by modulating the gut microbiome in mice. Front Nutr 2021; 8: 708096. doi: 10.3389/fnut.2021.708096

15.
Liu X, Zheng J, Li F, Yi R, Mu J, Tan F, et al. Lactobacillus plantarum HFY15 helps prevent retinoic acid-induced secondary osteoporosis in wistar rats. Evid Based Complement Alternat Med 2020; 2020: 2054389. doi: 10.1155/2020/2054389

16.
Sommer F, Backhed F. The gut microbiota – masters of host development and physiology. Nat Rev Microbiol 2013; 11(4): 227–38. doi: 10.1038/nrmicro2974

17.
Lei M, Hua LM, Wang DW. The effect of probiotic treatment on elderly patients with distal radius fracture: a prospective double-blind, placebo-controlled randomised clinical trial. Benef Microbes 2016; 7(5): 631–7. doi: 10.3920/BM2016.0067

18.
Lambert MNT, Thybo CB, Lykkeboe S, Rasmussen LM, Frette X, Christensen LP, et al. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial. Am J Clin Nutr 2017; 106(3): 909–20. doi: 10.3945/ajcn.117.153353

19.
Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013; 28(1): 2–17. doi: 10.1002/jbmr.1805

20.
Cui L, Li T, Liu Y, Zhou L, Li P, Xu B, et al. Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis. PLoS One 2012; 7(4): e34647. doi: 10.1371/journal.pone.0034647

21.
Lin SE, Huang JP, Wu LZ, Wu T, Cui L. Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. Biomed Environ Sci 2013; 26(4): 249–57.

22.
Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423(6937): 337–42. doi: 10.1038/nature01658

23.
Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012; 11(3): 234–50. doi: 10.1038/nrd3669

24.
Tsao YT, Huang YJ, Wu HH, Liu YA, Liu YS, Lee OK. Osteocalcin mediates biomineralization during osteogenic maturation in human mesenchymal stromal cells. Int J Mol Sci 2017; 18(1): 159. doi: 10.3390/ijms18010159

25.
Lv Y, Wang G, Xu W, Tao P, Lv X, Wang Y. Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear kappaB ligand. Exp Ther Med 2015; 9(1): 143–6. doi: 10.3892/etm.2014.2071

26.
Ottewell PD. The role of osteoblasts in bone metastasis. J Bone Oncol 2016; 5(3): 124–7. doi: 10.1016/j.jbo.2016.03.007

27.
Prideaux M, Findlay DM, Atkins GJ. Osteocytes: the master cells in bone remodelling. Curr Opin Pharmacol 2016; 28: 24–30. doi: 10.1016/j.coph.2016.02.003

28.
Sjogren K, Engdahl C, Henning P, Lerner UH, Tremaroli V, Lagerquist MK, et al. The gut microbiota regulates bone mass in mice. J Bone Miner Res 2012; 27(6): 1357–67. doi: 10.1002/jbmr.1588

29.
Fu C, Shi R. Osteoclast biology in bone resorption: a review. STEMedicine 2020; 1(4): e57. doi: 10.37175/stemedicine.v1i4.57

30.
Takahashi M, Ushijima K, Hayashi Y, Maekawa T, Ando H, Tsuruoka S, et al. Dosing-time dependent effect of dexamethasone on bone density in rats. Life Sci 2010; 86(1–2): 24–9. doi: 10.1016/j.lfs.2009.10.020

31.
Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102(2): 274–82. doi: 10.1172/JCI2799

32.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130(3): 456–69. doi: 10.1016/j.cell.2007.05.047

33.
Poser JW, Esch FS, Ling NC, Price PA. Isolation and sequence of the vitamin K-dependent protein from human bone. Undercarboxylation of the first glutamic acid residue. J Biol Chem 1980; 255(18): 8685–91. doi: 10.1016/S0021-9258(18)43554-5

34.
Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Rev Endocr Metab Disord 2015; 16(2): 93–8. doi: 10.1007/s11154-014-9307-7

35.
Lamp EC, Drexler HG. Biology of tartrate-resistant acid phosphatase. Leuk Lymphoma 2000; 39(5–6): 477–84. doi: 10.3109/10428190009113378

36.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93(2): 165–76. doi: 10.1016/S0092-8674(00)81569-X

37.
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95(7): 3597–602. doi: 10.1073/pnas.95.7.3597

38.
Silva I, Branco JC. Rank/Rankl/opg: literature review. Acta Reumatol Port 2011; 36(3): 209–18.

39.
Gao YH, Shinki T, Yuasa T, Kataoka-Enomoto H, Komori T, Suda T, et al. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). Biochem Biophys Res Commun 1998; 252(3): 697–702. doi: 10.1006/bbrc.1998.9643

40.
Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997; 234(1): 137–42. doi: 10.1006/bbrc.1997.6603

41.
Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998; 161(11): 6113–21. doi: 10.4049/jimmunol.161.11.6113

42.
Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003; 14(3–4): 251–63. doi: 10.1016/S1359-6101(03)00027-3

Lactobacillus plantarum LP45 inhibits the RANKL/OPG signaling pathway and prevents glucocorticoid-induced osteoporosis

Abstract

Downloads

References